ChemPartner PharmaTech Co Ltd - Asset Resilience Ratio
ChemPartner PharmaTech Co Ltd (300149) has an Asset Resilience Ratio of 1.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300149 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how ChemPartner PharmaTech Co Ltd's Asset Resilience Ratio has changed over time. See ChemPartner PharmaTech Co Ltd (300149) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ChemPartner PharmaTech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ChemPartner PharmaTech Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥33.99 Million | 1.67% |
| Total Liquid Assets | CN¥33.99 Million | 1.67% |
Asset Resilience Insights
- Limited Liquidity: ChemPartner PharmaTech Co Ltd maintains only 1.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ChemPartner PharmaTech Co Ltd Industry Peers by Asset Resilience Ratio
Compare ChemPartner PharmaTech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for ChemPartner PharmaTech Co Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for ChemPartner PharmaTech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.24% | CN¥45.57 Million ≈ $6.67 Million |
CN¥2.03 Billion ≈ $297.48 Million |
+2.19pp |
| 2024-12-31 | 0.05% | CN¥1.05 Million ≈ $153.04K |
CN¥2.00 Billion ≈ $292.05 Million |
-0.04pp |
| 2023-12-31 | 0.09% | CN¥2.21 Million ≈ $322.75K |
CN¥2.43 Billion ≈ $356.22 Million |
-0.36pp |
| 2021-12-31 | 0.45% | CN¥18.98 Million ≈ $2.78 Million |
CN¥4.22 Billion ≈ $617.17 Million |
-0.04pp |
| 2020-12-31 | 0.49% | CN¥20.08 Million ≈ $2.94 Million |
CN¥4.12 Billion ≈ $603.12 Million |
-1.22pp |
| 2019-12-31 | 1.71% | CN¥64.40 Million ≈ $9.42 Million |
CN¥3.77 Billion ≈ $551.34 Million |
-10.21pp |
| 2017-12-31 | 11.92% | CN¥124.34 Million ≈ $18.19 Million |
CN¥1.04 Billion ≈ $152.65 Million |
-27.54pp |
| 2016-12-31 | 39.46% | CN¥313.00 Million ≈ $45.80 Million |
CN¥793.16 Million ≈ $116.06 Million |
-3.92pp |
| 2015-12-31 | 43.39% | CN¥328.00 Million ≈ $48.00 Million |
CN¥756.00 Million ≈ $110.63 Million |
+38.26pp |
| 2014-12-31 | 5.13% | CN¥38.00 Million ≈ $5.56 Million |
CN¥741.13 Million ≈ $108.45 Million |
-- |
About ChemPartner PharmaTech Co Ltd
Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehe… Read more